Israel Institute of Technology, Rappaport Faculty of Medicine
Dr. Rosenberg joined D-Pharm in 2000. Prior to that Dr. Rosenberg was Medical Director for Merck, Sharp and Dohme's Israeli subsidiary. He graduated cum laude from the Rappaport Faculty of Medicine of the Technion, Israel Institute of Technology in ...
Dr. Gilad RosenbergVice President for Clinical DevelopmentDr. Rosenberg joined the Company in 2000.Prior to that Dr. Rosenberg was Medical Director for Merck, Sharp and Dohme's Israeli subsidiary.He graduated cum laude from the Rappaport Faculty of Medicine of the Technion, Israel Institute of Technology in 1992, and received post-graduate training in neurology at the Hadassah Medical Center, Jerusalem.Dr. Rosenberg also holds an MSc in neuroscience, with distinction, from the University of Oxford.
Dr. Gilad Rosenberg, D-Pharm's VP of Clinical Development commented, "It is very gratifying see that the reduced rates of brain swelling - an adverse phenomenon likely enhanced by tPA's neurotoxic effects - do translate into less disability and better neurological recovery in tPA-treated stroke patients receiving THR-18."
Browse ZoomInfo's company directory. Our company profiles include corporate background information, detailed descriptions, and links to comprehensive employee profiles with verified contact information.